寻找幽门螺杆菌生物膜生产替代抑制剂的硅片分析。

Debasmita Bhattacharya, Jai Gupta, Avi Gupta, Moupriya Nag, Dibyajit Lahiri, Debanjan Mitra
{"title":"寻找幽门螺杆菌生物膜生产替代抑制剂的硅片分析。","authors":"Debasmita Bhattacharya, Jai Gupta, Avi Gupta, Moupriya Nag, Dibyajit Lahiri, Debanjan Mitra","doi":"10.2174/0115701638369494250723071458","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Antibiotic Resistance is a growing concern in the current world. Regarding this, Helicobacter pylori is known to be present in the digestive tracts of human beings. In some people, the infection leads to stomach cancer. With the increasing problem of Antibiotic resistance, reports show that drugs are no longer working with the same efficacy rate as they used to. The present work is a study of the two-component Acid-Response System (ArsRS) protein, one of the key pro-teins involved in biofilm formation by H. pylori.</p><p><strong>Methods: </strong>In this study, an overall bioinformatics analysis was conducted of the bioactive compound, along with some FDA-approved drugs, to identify potential novel treatments for diseases associated with H. pylori. The molecular docking studies have been done with common drugs that are used for the treatment of the infection caused by H. pylori as Amoxicillin, Clarithromycin, Tetracycline, Levofloxacin, Metronidazole, Omeprazole, and Rabeprazole. Another aspect of the current study was to investigate the potential for national compounds such as Quercetin, α-mangostin, Phytol, Liquiri-tin, and D-mannitol as an alternative therapeutic agent. ADMET Analysis and toxicity assessment were done to check the pharmacokinetics of the bioactive compounds. An in silico investigation of the H. pylori protein revealed its stability and compactness.</p><p><strong>Results: </strong>A Higher number of intra-protein interactions increases the stability of H. pylori protein. Liquiritin emerged as an active molecule that can be used for inhibiting H. pylori biofilms. The FDA-approved drug Clarithromycin showed the highest binding energy among the synthetic group.</p><p><strong>Discussions: </strong>The target protein's structural and sequential analysis demonstrated how the correct number of amino acids boosts the protein's stability. The ability of bioactive chemicals to function as medications is indicated by their drug-likeness characteristics. According to toxicity evaluation, they do not have any serious effects when they come into contact with people through the environment. Liquiritin and Clarithromycin were the two top compounds that appeared as the best inhibitors.</p><p><strong>Conclusions: </strong>Bioactive compounds that can be used as drugs. This work will also be beneficial for the development of synthetic drugs.</p>","PeriodicalId":93962,"journal":{"name":"Current drug discovery technologies","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"In silico Analysis to Search for an Alternative Inhibitor of Biofilm Production by Helicobacter pylori.\",\"authors\":\"Debasmita Bhattacharya, Jai Gupta, Avi Gupta, Moupriya Nag, Dibyajit Lahiri, Debanjan Mitra\",\"doi\":\"10.2174/0115701638369494250723071458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Antibiotic Resistance is a growing concern in the current world. Regarding this, Helicobacter pylori is known to be present in the digestive tracts of human beings. In some people, the infection leads to stomach cancer. With the increasing problem of Antibiotic resistance, reports show that drugs are no longer working with the same efficacy rate as they used to. The present work is a study of the two-component Acid-Response System (ArsRS) protein, one of the key pro-teins involved in biofilm formation by H. pylori.</p><p><strong>Methods: </strong>In this study, an overall bioinformatics analysis was conducted of the bioactive compound, along with some FDA-approved drugs, to identify potential novel treatments for diseases associated with H. pylori. The molecular docking studies have been done with common drugs that are used for the treatment of the infection caused by H. pylori as Amoxicillin, Clarithromycin, Tetracycline, Levofloxacin, Metronidazole, Omeprazole, and Rabeprazole. Another aspect of the current study was to investigate the potential for national compounds such as Quercetin, α-mangostin, Phytol, Liquiri-tin, and D-mannitol as an alternative therapeutic agent. ADMET Analysis and toxicity assessment were done to check the pharmacokinetics of the bioactive compounds. An in silico investigation of the H. pylori protein revealed its stability and compactness.</p><p><strong>Results: </strong>A Higher number of intra-protein interactions increases the stability of H. pylori protein. Liquiritin emerged as an active molecule that can be used for inhibiting H. pylori biofilms. The FDA-approved drug Clarithromycin showed the highest binding energy among the synthetic group.</p><p><strong>Discussions: </strong>The target protein's structural and sequential analysis demonstrated how the correct number of amino acids boosts the protein's stability. The ability of bioactive chemicals to function as medications is indicated by their drug-likeness characteristics. According to toxicity evaluation, they do not have any serious effects when they come into contact with people through the environment. Liquiritin and Clarithromycin were the two top compounds that appeared as the best inhibitors.</p><p><strong>Conclusions: </strong>Bioactive compounds that can be used as drugs. This work will also be beneficial for the development of synthetic drugs.</p>\",\"PeriodicalId\":93962,\"journal\":{\"name\":\"Current drug discovery technologies\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current drug discovery technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0115701638369494250723071458\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug discovery technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115701638369494250723071458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

导言:抗生素耐药性是当今世界日益关注的问题。对此,已知幽门螺杆菌存在于人类的消化道中。对一些人来说,这种感染会导致胃癌。随着抗生素耐药性问题的日益严重,报告显示,药物不再像过去那样有效。本工作是对双组分酸反应系统(ArsRS)蛋白的研究,该蛋白是参与幽门螺杆菌生物膜形成的关键蛋白之一。方法:在本研究中,对该生物活性化合物以及一些fda批准的药物进行了全面的生物信息学分析,以确定与幽门螺杆菌相关疾病的潜在新治疗方法。常用的治疗幽门螺杆菌感染的药物,如阿莫西林、克拉霉素、四环素、左氧氟沙星、甲硝唑、奥美拉唑和雷贝拉唑,进行了分子对接研究。本研究的另一个方面是研究槲皮素、α-山竹苷、叶绿醇、利基里苷和d -甘露醇等天然化合物作为替代治疗药物的潜力。采用ADMET分析和毒性评价方法检测活性化合物的药代动力学。幽门螺杆菌蛋白的计算机研究显示其稳定性和致密性。结果:较多的蛋白内相互作用增加了幽门螺杆菌蛋白的稳定性。甘草素是一种抑制幽门螺旋菌生物膜的活性分子。fda批准的药物克拉霉素在合成组中显示出最高的结合能。讨论:目标蛋白的结构和序列分析证明了正确数量的氨基酸如何提高蛋白质的稳定性。生物活性化学物质作为药物发挥作用的能力是由它们与药物相似的特性表明的。根据毒性评价,它们通过环境与人接触后不会产生严重影响。甘草素和克拉霉素是最佳抑制剂。结论:该化合物具有生物活性,可作为药物使用。这项工作也将有利于合成药物的开发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
In silico Analysis to Search for an Alternative Inhibitor of Biofilm Production by Helicobacter pylori.

Introduction: Antibiotic Resistance is a growing concern in the current world. Regarding this, Helicobacter pylori is known to be present in the digestive tracts of human beings. In some people, the infection leads to stomach cancer. With the increasing problem of Antibiotic resistance, reports show that drugs are no longer working with the same efficacy rate as they used to. The present work is a study of the two-component Acid-Response System (ArsRS) protein, one of the key pro-teins involved in biofilm formation by H. pylori.

Methods: In this study, an overall bioinformatics analysis was conducted of the bioactive compound, along with some FDA-approved drugs, to identify potential novel treatments for diseases associated with H. pylori. The molecular docking studies have been done with common drugs that are used for the treatment of the infection caused by H. pylori as Amoxicillin, Clarithromycin, Tetracycline, Levofloxacin, Metronidazole, Omeprazole, and Rabeprazole. Another aspect of the current study was to investigate the potential for national compounds such as Quercetin, α-mangostin, Phytol, Liquiri-tin, and D-mannitol as an alternative therapeutic agent. ADMET Analysis and toxicity assessment were done to check the pharmacokinetics of the bioactive compounds. An in silico investigation of the H. pylori protein revealed its stability and compactness.

Results: A Higher number of intra-protein interactions increases the stability of H. pylori protein. Liquiritin emerged as an active molecule that can be used for inhibiting H. pylori biofilms. The FDA-approved drug Clarithromycin showed the highest binding energy among the synthetic group.

Discussions: The target protein's structural and sequential analysis demonstrated how the correct number of amino acids boosts the protein's stability. The ability of bioactive chemicals to function as medications is indicated by their drug-likeness characteristics. According to toxicity evaluation, they do not have any serious effects when they come into contact with people through the environment. Liquiritin and Clarithromycin were the two top compounds that appeared as the best inhibitors.

Conclusions: Bioactive compounds that can be used as drugs. This work will also be beneficial for the development of synthetic drugs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信